On February 24, 2021 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, reported that Rob Ross, M.D., incoming chief executive officer, will participate in the following virtual investor conferences (Press release, Surface Oncology, FEB 24, 2021, View Source [SID1234575510]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 41st Annual Healthcare Conference, Monday, March 1, 2021, at 10:20 a.m. ET as part of the Novel IO panel.

H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021, presentation recording will be available to investors during the course of the conference.
The presentations will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging pre-clinical program, SRF114 (targeting CCR8).